ArticleRheumatology (Oxford, England)2026
A new characteristic of SLE: subclinical vein involvement-an in-depth biochemical and imaging study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.Journal of gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSLE is a heterogeneous autoimmune disorder often complicated by vascular events, with or without antiphospholipid antibody syndrome (APS). This study aimed to explore subclinical venous involvement in SLE using biochemical and imaging modalities, focusing on vein wall thickness (VWT) and inflammation-related biomarkers.
methodsIn this cross-sectional study, 68 SLE patients were categorized based on antiphospholipid antibody (APA) status and clinical APS. Results were compared with 22 RA patients and 20 healthy controls. Serum levels of P-selectin, growth differentiation factor 15 (GDF15) and citrullinated histone 3 (CH3) were measured using ELISA. Ultrasonographic assessments evaluated VWT at bilateral jugular veins, femoral veins, portal vein and femoral artery. Correlations and predictors of vascular changes were analysed statistically.
resultsVWT was significantly increased in SLE patients compared with both the control groups (P < 0.001), regardless of APA and APS status. Serum P-selectin, GDF15 and CH3 levels were elevated in SLE-APS patients. GDF15 levels correlated positively with VWT, and increased portal VWT was independently associated with thrombosis. Biomarkers showed significant associations with APS, suggesting their role as indicators of prothrombotic states. No significant associations were found between vascular parameters and disease activity score.
conclusionSubclinical venous involvement appears to be a novel vascular feature of SLE, reflected by increased VWT and its association with thrombosis and biomarkers. Increased portal vein thickness may indicate vascular risk. Whether these changes result from inflammation or vascular remodelling remains unclear, but their presence irrespective of disease activity highlights their clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.